NEW YORK, August 11, 2026, 08:50 EDT
- Sionna shares closed 91.2% lower at $4.50 after a Phase 2a trial missed its main goal.
- SION-719 produced a 1 mmol/L placebo-adjusted sweat-chloride reduction, versus a roughly 10 mmol/L investor expectation.
- The closing equity value was about $203 million, below Sionna’s reported $268.3 million cash balance.
Sionna Therapeutics NASDAQ:SION closed 91.2% lower on Monday after its lead clinical readout failed. The company will not advance SION-719 as an add-on therapy in its current form.
The collapse left Sionna valued below its cash balance. That does not make the stock cheap by itself. It shows how quickly investors discounted future research spending and execution risk.
The central number was small. SION-719 reduced sweat chloride by only 1 mmol/L versus placebo when added to Trikafta. Investors had expected at least 10 mmol/L, according to RBC Capital Markets analyst Brian Abrahams.
| Trial and market measure | Result | Investor benchmark or comparison |
|---|---|---|
| Placebo-adjusted sweat-chloride reduction | 1 mmol/L | At least 10 mmol/L expected |
| Shortfall versus expectation | 9 mmol/L | 90% below the expected effect |
| Sionna close | $4.50 | Down 91.2% |
| Vertex close | $523.91 | Up 5.6% |
The 9 mmol/L gap and 90% shortfall are calculations from the reported values. The closing prices and moves came from the same session.
The result reversed the setup from four days earlier. Chief Executive Mike Cloonan had said, “We continued to advance our clinical NBD1 stabilizer programs during the second quarter as we approach two important clinical milestones this summer.” Sionna second-quarter release
SION-719 was generally well tolerated with Trikafta, but efficacy drove the valuation. The study also showed variable baseline measurements and inconsistent drug exposure between groups. Sionna said it would keep reviewing the data and preserve capital.
Vertex Pharmaceuticals NASDAQ:VRTX gained 5.6%. Its Trikafta franchise lost a potential add-on competitor. Abrahams called Sionna’s outcome “a clearing event for VRTX.” Investor’s Business Daily
The balance sheet now anchors the debate. Sionna held $268.3 million of cash, equivalents and marketable securities on June 30. Working capital was $205.3 million.
| Post-crash valuation measure | Value | Basis |
|---|---|---|
| Cash and marketable securities | $268.3 million | June 30 balance |
| Working capital | $205.3 million | June 30 balance |
| Weighted-average shares | 45.15 million | Second quarter |
| Cash per share | $5.94 | Calculated |
| Monday close | $4.50 | Market price |
| Implied equity value | $203.2 million | Calculated |
| Equity discount to cash | 24.3% | Calculated |
Cash per share uses the reported cash and 45.15 million weighted-average shares. The equity value uses Monday’s $4.50 close. These figures ignore liabilities, future burn and any difference between weighted-average and period-end shares.
That distinction matters. Second-quarter research spending was $21.9 million. General and administrative costs were $10.6 million. The net loss reached $29.9 million, up from $18.1 million a year earlier.
Wall Street’s published targets were set before the failure. They now document how much clinical value vanished, not a reliable measure of current upside.
| Firm | Published recommendation | Price target | Date |
|---|---|---|---|
| RBC Capital Markets | Underperform | $24 | Dec. 1, 2025 |
| Freedom Broker | Hold | $38 | May 20, 2026 |
| Stifel | Buy | $55 | May 18, 2026 |
| Raymond James | Strong Buy | $53 | May 12, 2026 |
The recommendations and targets came from the firms’ last reported actions before Monday’s data. RBC had already questioned the translation of early evidence. Freedom waited for the readout, while Stifel and Raymond James remained bullish.
Sionna still has other assets. Its SION-451 dual-combination program remains a separate development path. The company must decide whether the failed add-on result weakens confidence in the wider NBD1 approach.
Risks: Cash is not distributable value. Clinical work, restructuring and staff costs can erode it quickly. A second weak readout could force deeper cuts, while a credible pipeline reset could narrow the discount.
The next decision-relevant catalyst is management’s capital plan. Investors need a new cash-runway estimate and a clear verdict on SION-451 before treating the $65 million cash-to-equity gap as recoverable value.
